We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
10 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryOxlumo (lumasiran) has been approved for the treatment of primary hyperoxaluria type 1.
-
Prescription medicine decision summaryGivlaari (givosiran) is approved to treat acute hepatic porphyria.
-
Prescription medicine registrationActive ingredients: givosiran sodium.
-
Australian Public Assessment Report (AusPAR)AusPAR for Onpattro (patisiran) for treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
-
-
-
Prescription medicine decision summaryOnpattro (patisiran) is approved to treat polyneuropathy.
-
Prescription medicine registrationActive ingredients: patisiran.
-
-